Wall St set for best June in decades as G20 convenes

By Stephen Culp NEW YORK (Reuters) - Wall Street advanced on Friday, with the S&P 500 and the Dow on track for their best June in generations, ahead of the much-anticipated trade talks between U.S.

Reuters June 29, 2019 01:07:00 IST
Wall St set for best June in decades as G20 convenes

Wall St set for best June in decades as G20 convenes

By Stephen Culp

NEW YORK (Reuters) - Wall Street advanced on Friday, with the S&P 500 and the Dow on track for their best June in generations, ahead of the much-anticipated trade talks between U.S. President Donald Trump and his Chinese counterpart Xi Jinping at the G20 summit now underway in Japan.

All three major U.S. stock indexes were higher near the close of the week, month, quarter and first half of the year, during which the U.S. stock market has had a remarkable run.

The S&P 500 was poised to have its best June since 1955. The Dow was on track for its best June since 1938.

From the start of 2019, after investors fled equities amid fears of a global economic slowdown and sending stock markets tumbling in December, the benchmark S&P 500 is up 17%, its largest first-half increase since 1997.

"This has largely been a rebound from the fourth quarter," said Doug Cohen, managing director of portfolio management at Athena Capital Advisors in Boston. "Since then, the market's been able to climb the proverbial wall of worry."

Trump expressed hopes that his meeting with Xi at the Group of 20 summit will be productive, but said he had not made any promises about a reprieve from escalating tariffs.

"Right now, the consensus is that there will be a six-month reprieve from the tariff increases threatened by Trump. I think that's more or less baked in to the markets," Cohen added.

"People don't want to be on the wrong side of good news."

Financial stocks led the gains in the S&P 500 and the Dow after the big U.S. banks passed Federal Reserve's "stress test," with the central bank giving the companies a clean bill of health. The S&P 500 Bank index was up 2.4%.

The Dow Jones Industrial Average rose 56.08 points, or 0.21%, to 26,582.66, the S&P 500 gained 10.38 points, or 0.35%, to 2,935.3 and the Nasdaq Composite added 17.69 points, or 0.22%, to 7,985.45.

Of the 11 major sectors in the S&P 500, all but technology and healthcare were trading in positive territory.

Financials, energy and tariff-vulnerable industrials were the biggest percentage gainers.

Morgan Stanley advanced 1.6% following an exclusive Reuters report that the broker would likely gain majority control of its China securities joint venture in the latter half of the year.

Constellation Brands Inc reported better-than-expected quarterly results and raised its full-year guidance due to healthy beer demand, sending its shares up 5.5%.

In economic news, consumer spending rose moderately in May and prices edged higher, implying a slow-down in economic growth and benign inflation pressures, providing the Federal Reserve rationale for a possible interest rate cut in July.

Advancing issues outnumbered declining ones on the NYSE by a 2.97-to-1 ratio; on Nasdaq, a 2.72-to-1 ratio favored advancers.

The S&P 500 posted 13 new 52-week highs and no new lows; the Nasdaq Composite recorded 64 new highs and 34 new lows.

(Reporting by Stephen Culp; Editing by Nick Zieminski)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reports
Business

Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reports

(Reuters) - Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion, the Wall Street Journal reported on Saturday, citing people familiar with the matter. A deal for Immunomedics, which last month reported positive data from a late-stage study for its breast-cancer drug, could be announced Monday if not sooner, the Journal said https://www.wsj.com/articles/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-11599936777?mod=hp_lead_pos2. Gilead and Immunomedics did not respond immediately to emailed requests from Reuters for comment

China bans German pork imports after African swine fever case
Business

China bans German pork imports after African swine fever case

SHANGHAI (Reuters) - China banned pork imports from Germany on Saturday after it confirmed its first case of African swine fever last week, in a move set to hit German producers and push up global prices as China's meat supplies tighten. China's ban on imports from its third largest supplier comes as the world's top meat buyer deals with an unprecedented pork shortage after its own epidemic of the deadly hog disease. The ban on Germany, which has supplied about 14% of China's pork imports so far this year, will push up demand for meat from other major suppliers like the United States and Spain, boosting global prices.

Libya's Haftar committed to ending oil blockade, U.S. says
Business

Libya's Haftar committed to ending oil blockade, U.S. says

CAIRO (Reuters) - Libyan commander Khalifa Haftar has committed to ending a months-long blockade of oil facilities, the U.S.